96 related articles for article (PubMed ID: 24045366)
41. Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells.
Wang L; Huang T; Chen W; Gao X; Zhou T; Wu Z; Sun Y
Oncol Rep; 2012 Dec; 28(6):2043-8. PubMed ID: 22972438
[TBL] [Abstract][Full Text] [Related]
42. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer.
Saur D; Seidler B; Schneider G; Algül H; Beck R; Senekowitsch-Schmidtke R; Schwaiger M; Schmid RM
Gastroenterology; 2005 Oct; 129(4):1237-50. PubMed ID: 16230077
[TBL] [Abstract][Full Text] [Related]
43. [The effects of shRNA-CXCR4 on breast cancer cells migration and invasion].
Li HY; Ren GS; Tan JX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):393-7. PubMed ID: 19626989
[TBL] [Abstract][Full Text] [Related]
44. [The effects of CXCR4 inhibited by RNA interference on metastasis and invasion of breast cancer cell in vitro].
Zhang SC; Qiao L; Gao H
Zhonghua Wai Ke Za Zhi; 2007 Apr; 45(7):473-5. PubMed ID: 17686306
[TBL] [Abstract][Full Text] [Related]
45. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion.
Nasser MW; Qamri Z; Deol YS; Smith D; Shilo K; Zou X; Ganju RK
PLoS One; 2011; 6(9):e23901. PubMed ID: 21915267
[TBL] [Abstract][Full Text] [Related]
46. Downregulation of CXCR4 in Metastasized Breast Cancer Cells and Implication in Their Dormancy.
Nobutani K; Shimono Y; Mizutani K; Ueda Y; Suzuki T; Kitayama M; Minami A; Momose K; Miyawaki K; Akashi K; Azuma T; Takai Y
PLoS One; 2015; 10(6):e0130032. PubMed ID: 26083776
[TBL] [Abstract][Full Text] [Related]
47. Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases.
Portella L; Vitale R; De Luca S; D'Alterio C; Ieranò C; Napolitano M; Riccio A; Polimeno MN; Monfregola L; Barbieri A; Luciano A; Ciarmiello A; Arra C; Castello G; Amodeo P; Scala S
PLoS One; 2013; 8(9):e74548. PubMed ID: 24058588
[TBL] [Abstract][Full Text] [Related]
48. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4.
Cronin PA; Wang JH; Redmond HP
BMC Cancer; 2010 May; 10():225. PubMed ID: 20492653
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.
Liang Z; Wu T; Lou H; Yu X; Taichman RS; Lau SK; Nie S; Umbreit J; Shim H
Cancer Res; 2004 Jun; 64(12):4302-8. PubMed ID: 15205345
[TBL] [Abstract][Full Text] [Related]
50. Aquaporin-3 Controls Breast Cancer Cell Migration by Regulating Hydrogen Peroxide Transport and Its Downstream Cell Signaling.
Satooka H; Hara-Chikuma M
Mol Cell Biol; 2016 Feb; 36(7):1206-18. PubMed ID: 26830227
[TBL] [Abstract][Full Text] [Related]
51. CXCR4 targeted dendrimer for anti-cancer drug delivery and breast cancer cell migration inhibition.
Chittasupho C; Anuchapreeda S; Sarisuta N
Eur J Pharm Biopharm; 2017 Oct; 119():310-321. PubMed ID: 28694161
[TBL] [Abstract][Full Text] [Related]
52. Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.
Wilkinson RA; Pincus SH; Song K; Shepard JB; Weaver AJ; Labib ME; Teintze M
Bioorg Med Chem Lett; 2013 Apr; 23(7):2197-201. PubMed ID: 23434419
[TBL] [Abstract][Full Text] [Related]
53. CXCR4-antagonist Peptide R-liposomes for combined therapy against lung metastasis.
Ieranò C; Portella L; Lusa S; Salzano G; D'Alterio C; Napolitano M; Buoncervello M; Macchia D; Spada M; Barbieri A; Luciano A; Barone MV; Gabriele L; Caraglia M; Arra C; De Rosa G; Scala S
Nanoscale; 2016 Apr; 8(14):7562-71. PubMed ID: 26983756
[TBL] [Abstract][Full Text] [Related]
54. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells.
Yagi H; Tan W; Dillenburg-Pilla P; Armando S; Amornphimoltham P; Simaan M; Weigert R; Molinolo AA; Bouvier M; Gutkind JS
Sci Signal; 2011 Sep; 4(191):ra60. PubMed ID: 21934106
[TBL] [Abstract][Full Text] [Related]
55. Aberrant expression of CXCR4 significantly contributes to metastasis and predicts poor clinical outcome in breast cancer.
Yang P; Liang SX; Huang WH; Zhang HW; Li XL; Xie LH; Du CW; Zhang GJ
Curr Mol Med; 2014 Jan; 14(1):174-84. PubMed ID: 24256053
[TBL] [Abstract][Full Text] [Related]
56. Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
Pan H; Peng Z; Lin J; Ren X; Zhang G; Cui Y
Cancer Sci; 2018 Dec; 109(12):3794-3804. PubMed ID: 30290049
[TBL] [Abstract][Full Text] [Related]
57. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain.
Hinton CV; Avraham S; Avraham HK
Clin Exp Metastasis; 2010 Feb; 27(2):97-105. PubMed ID: 18814042
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer.
Singh B; Cook KR; Martin C; Huang EH; Mosalpuria K; Krishnamurthy S; Cristofanilli M; Lucci A
Clin Exp Metastasis; 2010 Apr; 27(4):233-40. PubMed ID: 20229045
[TBL] [Abstract][Full Text] [Related]
59. Silencing of CXCR4 blocks breast cancer metastasis.
Liang Z; Yoon Y; Votaw J; Goodman MM; Williams L; Shim H
Cancer Res; 2005 Feb; 65(3):967-71. PubMed ID: 15705897
[TBL] [Abstract][Full Text] [Related]
60. Preferential, enhanced breast cancer cell migration on biomimetic electrospun nanofiber 'cell highways'.
Nelson MT; Short A; Cole SL; Gross AC; Winter J; Eubank TD; Lannutti JJ
BMC Cancer; 2014 Nov; 14():825. PubMed ID: 25385001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
